FAST presents the Strategic Research Agenda for Targeted Radionuclide Therapy: a field-driven agenda that guides the further development of this promising but still relatively young field within oncology care. With clear priorities and targeted actions, the agenda provides a foundation for better collaboration, more effective use of resources, and accelerated innovation. To make TRT available to patients more quickly and on a broader scale.

Targeted Radionuclide Therapy (TRT) uses radiopharmaceuticals that specifically target molecular targets in diseased tissue and deliver therapeutic radiation locally. By combining diagnostics and therapy, TRT offers unique opportunities for targeted treatment and personalized dosing. The Netherlands has a strong knowledge base and specialized infrastructure for TRT. The next step is now to strengthen these in a targeted manner and organize them sustainably. With this vision, researchers, clinicians, companies, policymakers, and patient representatives have jointly drawn up the Strategic Research Agenda for TRT. This establishes a shared course for the development and application of radiopharmaceuticals.

TRT represents one of the most promising developments in oncological care, with potential for broader application in the future. The impact on patients is significant, particularly for those with limited treatment options. To realize this potential, targeted decisions, joint investments, and structural collaboration are necessary. The agenda brings these elements together and translates ambition into concrete priorities.

The agenda does not mark the end, but rather the beginning of the next phase: translating research into practice. This requires new forms of collaboration—between academia and industry, between development and application—and close coordination with regulators and patients. At the same time, it is clear that additional, structural funding is essential to ensure the necessary research infrastructure and collaboration in a sustainable manner.

From Agenda to Action on April 8
On April 8, the TRT Strategic Research Agenda will not only be launched but immediately put into action. This meeting will focus on concrete next steps: from forming consortia around priority themes to exploring targeted funding opportunities. This makes it the perfect time to get involved, help shape the agenda, and work together to implement it.

We cordially invite you to attend and actively contribute to the next phase of TRT in the Netherlands.

With this agenda, FAST, together with its partners, underscores its ambition to strengthen structural collaboration and bring innovation in advanced therapies to patients more quickly in a sustainable manner. By prioritizing and investing jointly now, the Netherlands can continue to play a leading role internationally in this strategic domain.

Follow NUCMED-NL’s activities here and sign up for the newsletter.